Trials Sponsors Conditions Drugs Pricing

Conditions

Hepatocellular Carcinoma

Keywords

hypovolemic phlebotomylow central venous pressuregoal-directedlaparoscopic hepatectomy

Outcome Measures

Primary Outcomes (1)

The proportion of allogeneic red blood cell products transfusion
The primary end point of the study was the proportion of patients who required transfusion of allogeneic red blood cell products during laparoscopic hepatectomy or at any time during the hospitalization during the index admission.
From date of operation until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 12 months.

Secondary Outcomes (17)

The volume of Phlebotomy
From the start of operation until the end of operation.
The volume of Intraoperative blood loss
From the start of operation until the end of operation (during the operation).
The volume of Allogeneic transfusion (perioperative)
From date of operation until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 12 months.
The volume of Allogeneic transfusion (postoperative)
From the end of operation until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 12 months.
The volume of Allogeneic transfusion (intraoperative)
From the start of operation until the end of operation.
+12 more secondary outcomes

Study Arms (2)

hypovolemic phlebotomy (HP)

EXPERIMENTAL

patients in this group undergoing laparoscopic hepatectomy was performed with goal-directed LCVP based on hypovolemic phlebotomy (HP)

Procedure: hypovolemic phlebotomy

Control

NO INTERVENTION

patients in this group undergoing laparoscopic hepatectomy was performed with LCVP but no hypovolemic phlebotomy (HP)

Interventions

hypovolemic phlebotomyProcedure

hypovolemic phlebotomy was performed after induction of anesthesia and before the star of parenchymal division, with a goal-directed low central venous pressure drop to 5mmHg.

Also known as: HP

hypovolemic phlebotomy (HP)

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Clinical diagnosis of Hepatocellular Carcinoma
Preference for laparoscopic hepatectomy and patient agreement

You may not qualify if:

Sponsors & Collaborators

The First Affiliated Hospital with Nanjing Medical University
Otherlead

Study Sites (1)

The First Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, 210029, China

RECRUITING

Shijiang LiuCONTACT+86-25-68303569 liushijiang@jsph.org.cn

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsLiver NeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesLiver Diseases

Study Officials

Shijiang Liu, MD
The First Affiliated Hospital with Nanjing Medical University
PRINCIPAL INVESTIGATOR

Central Study Contacts

Shijiang Liu, MD

CONTACT

+862568303569 liushijiang@jsph.org.cn

Yue Wang

CONTACT

+862568136360

Study Design

Study Type: interventional
Phase: not applicable
Allocation: RANDOMIZED
Masking: QUADRUPLE
Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Clinical Professor

Study Record Dates

First Submitted

March 1, 2023

First Posted

June 5, 2023

Study Start

May 1, 2022

Actual (reported)

Primary Completion

January 1, 2026

Estimated (date passed)

Goal-directed LCVP Based on HP in Laparoscopic Hepatectomy

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (17)

Study Arms (2)

hypovolemic phlebotomy (HP)

Control

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (17)

Study Arms (2)

hypovolemic phlebotomy (HP)

Control

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

Source record

Locations